IO Biotech

IO Biotech Enterprise Value

Delisted·Sep 22, 2026

The Enterprise Value (EV) of IO Biotech (IOBT) as of Nov 20, 2026 is -31.52 M USD. In the previous year, Enterprise Value (EV) was -114.11 M USD — a change of -72.37% (higher).

Enterprise Value

-31.52 MUSD

YoY

-72.37%

Last updated:

Enterprise Value (EV) of IO Biotech is 2024 -31.52 M USD. Enterprise Value (EV) of IO Biotech was 2023 -114.11 M USD. It decreases by -72.37% higher compared to the previous year.

The IO Biotech Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2019
27.41 M USD
Jan 1, 2020
23.19 M USD
Jan 1, 2021
-184.94 M USD
Jan 1, 2022
-113.21 M USD
Jan 1, 2023
-114.11 M USD
Jan 1, 2024
-31.52 M USD
The IO Biotech Enterprise Value history
YEAREnterprise ValueYoY
-31.52 MUSD-72.37%
-114.11 MUSD+0.79%
-113.21 MUSD-38.79%
-184.94 MUSD-897.59%
23.19 MUSD-15.40%
27.41 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IO Biotech Stock analysis

What does IO Biotech do? IO Biotech, Inc. develops immune modulating cancer therapies using its T-win technology platform. The Company focuses on product candidates that target immunosuppressive proteins like IDO and PD-L1, aiming to disrupt tumor-induced immunosuppression. Its lead candidate, IO102-IO103, is designed to address multiple pathways regulated by these proteins. The firm's pipeline includes therapies leveraging T-win to target the tumor microenvironment (TME). IO Biotech's revenue model is based on the development and potential commercialization of its product candidates. The company generates income through partnerships with pharmaceutical firms for the development and licensing of its therapies. These partnerships are formed with entities interested in advancing immune modulating cancer treatments. The target market includes pharmaceutical companies seeking innovative cancer therapy solutions. The firm's technology platform, T-win, is central to its business strategy. By targeting key immunosuppressive proteins such as IDO and PD-L1, IO Biotech addresses a critical need in cancer treatment. Its lead product candidate, IO102-IO103, is positioned to disrupt multiple immunosuppressive pathways, offering a novel approach to cancer therapy. IO Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IO Biotech stock

Enterprise Value (EV) of IO Biotech is -31.52 M USD in 2024.

Enterprise Value (EV) of IO Biotech changed from -114.11 M USD to -31.52 M USD, representing a -72.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) IO Biotech since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s IO Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — IO Biotech

All Key Metrics — IO Biotech